Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04665947 · ClinicalTrials.gov registry record · Early Phase 1
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
A Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04665947 is a Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04665947, a Early Phase 1 study of Metastatic Pancreatic Cancer and Locally Advanced Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DRUG [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Study Locations (1)
California
- University of California Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04665947
The ClinicalTrials.gov registry entry for NCT04665947 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. is the first listed.
NCT04665947 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04665947 about?
NCT04665947 is a clinical study titled "First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer". This is a Phase I, first-in-human study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or metastatic pancreatic adenocarcinoma (PDAC).
What is the current status of trial NCT04665947?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2020-12-18. Estimated completion is 2026-06.
What conditions does trial NCT04665947 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04665947?
The interventions under investigation include: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. (DRUG).
Who is sponsoring clinical trial NCT04665947?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04665947 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
RECRUITING · Phase 1
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Pancreatic Cancer
All registered trials for this condition
Locally Advanced Pancreatic Adenocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.